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Abstract
Background: Cardiovascular and diabetic disease are the leading and preventable causes of death
worldwide. The currently prognosticated dramatic increase in disease burden over the next two
decades, however, bespeaks a low confidence in our prevention ability. This conflicts with the
almost enthusiastic reporting of study results, which demonstrate substantial risk reductions
secondary to simple lifestyle changes.
Discussion: There is a case to be made for a disregard of the difference between statistical
significance and clinical relevance of the reported data. Nevertheless, lifestyle change remains the
main weapon in our battle against the epidemic of cardiometabolic disease. But along the way from
risk screening to intervention to maintenance the compound inefficiencies of current primary
preventive strategies marginalize their impact.
Summary: Unless we dramatically change the ways in which we deploy preventive interventions
we will inevitably lose the battle. In this paper we will argue for three provocative strategy changes,
namely (a) the disbanding of screening in favor of population-wide enrollment into preventive
interventions, (b) the substitution of the current cost utility analysis for a return-on-investment
centered appraisal of interventions, and (c) the replacement of standardized programs modeled
around acute care by individualized and perpetual interventions.
Background
Chronic cardiometabolic disease has become a prominent
public health concern chiefly for a unique combination of
three prospects:
a) pandemic and costly: its constituent diseases lead in the
mortality statistics [1-3] and in the top 10 ranks of the
most costly diseases [4].
b) predictable: aberrant vital parameters identify at-risk
individuals
c) preventable: lifestyle change prevents disease in at-risk
individuals
While the first observation is incontestable, the second
and third are not. In the following we will challenge some
of the notions on which our prevention strategies have
been based. We will provide evidence to the fact that our
current prevention efforts are inadequate to yield a signif-
icant reduction of the epidemic of cardiometabolic dis-
eases. We will argue that our current prevention strategies
fail to achieve their objective for three reasons:
Published: 21 February 2009
BMC Public Health 2009, 9:64 doi:10.1186/1471-2458-9-64
Received: 2 September 2008
Accepted: 21 February 2009
This article is available from: http://www.biomedcentral.com/1471-2458/9/64
© 2009 Kraushaar and Krämer; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Public Health 2009, 9:64 http://www.biomedcentral.com/1471-2458/9/64
Page 2 of 9
(page number not for citation purposes)
1. inefficiencies of screening
2. inefficiencies of intervention
3. inappropriate economic principles
From the discussion of these three aspects we will (a) pro-
pose a statistical tool to analyze intervention efficiency
and make comparable the results across interventions,
and (b) outline the features of an individualized popula-
tion strategy aimed at a substantial reduction of disease
incidence and prevalence.
Discussion
Methodically sound efforts to investigate the effects of
lifestyle modification on the risk of developing chronic
disease are relatively recent [5]. Their results are impres-
sive, with investigators reporting such dramatic risk reduc-
tions that medical associations now recommend lifestyle
change as the primary tool for the prevention of CVD and
Diabetes [6,7]. Table 1 lists the ubiquitously quoted rand-
omized case-control studies which investigated the effects
of exercise and dietary habit change on the progression
from pre-diabetic states to overt diabetes [8-11].
Exemplary are the DPP and the DPS, each reporting a rel-
ative 58% reduction in incident diabetes in subjects with
a pre-diabetic impairment of glucose tolerance (IGT) who
participated in the trials' lifestyle change intervention
arms.
Besides the obvious conclusions these trials are informa-
tive for the study and development of preventive strategies
for two reasons:
(a) Disease incidence rather than intermediate variables
such as risk factors ought to be the outcome measure.
(b) Results should be reported in absolute rather than rel-
ative terms, as the former provides for a more realistic
grasp of the intervention's impact on disease incidence.
Here is why:
At the end of the three-year DPS study period there was no
significant change in fasting plasma glucose (FPG) or
post-load glucose (PLG) for either the intervention or the
control group [12]. Hidden behind this lack of effect on
the intermediate variables of glucose metabolism was a
considerable reduction in progression to overt diabetes:
Only 8.6% of the subjects of the intervention group had
progressed from impaired glucose tolerance (IGT) to overt
diabetes vs. 19.8% in the control group. In absolute terms,
that is an 11.2% risk reduction, which translates into the
more impressive looking relative risk reduction of 58%.
That is in congruence with the DPP trial. But, an examina-
tion of the latter intervention's effect on CVD demon-
strated a significant improvement in risk factors (blood
pressure, triglycerides, LDL- and HDL-cholesterol), yet the
intervention group's CVD incidents exceeded slightly,
though insignificantly, those in the control group [13].
This apparent disconnect between risk factor and disease
suggests an insufficient knowledge of the cause-effect rela-
tionship between risk parameters and disease outcome.
That should show in inefficiencies of disease prediction
and risk screening.
The Inefficiencies of prediction and screening
Diabetes
Anderwald et al. investigated the utility of blood glucose
values and insulin resistance indices as tools to stratify for
diabetes risk [14]. They found no differences in fasted and
PLG values between normal controls and apparently
healthy offspring of type 2 diabetics who carry a substan-
tially elevated risk for diabetes and its CVD consequences
[15].
But the observed difference in peripheral insulin resist-
ance (IR) as well as in insulin mediated suppression of
hepatic glucose production [14] does not necessarily
make IR a better risk predictor than PLG. IR has been
found to predict diabetes risk only in individuals with a
family history of the disease but not in those without [16].
Table 1: Diabetes Prevention Studies
Study Relative risk reduction
DaQing IGT and Diabetes Study 40%
The Finnish Diabetes Prevention Study (DPS) 58%
The U.S. Diabetes Prevention Program 58%
The Japanese Trial of IGT Males 68%BMC Public Health 2009, 9:64 http://www.biomedcentral.com/1471-2458/9/64
Page 3 of 9
(page number not for citation purposes)
CVD
In the ARIC study population and in a group of 5,000 Brit-
ish men the metabolic syndrome (MS) was found to
approximately double CVD risk [17,18].
However, clinical reality puts statistical significance into
perspective: two thirds of all first cases of non-fatal and
fatal CVD occurred in those who did not meet the MS
diagnostic criteria [17,18].
In the study of Wannamethee et al. the sensitivity and spe-
cificity of the MS as a predictor of disease incidence was
0.35 and 0.76 respectively [18]. And 80% of those classi-
fied as at-risk were false positives.
That is insufficient for impact. The proportion of CVD that
would be prevented in the MS-positive population if the
MS were prevented (the attributable proportion in the
exposed, APe), and the proportion of CVD that would cor-
respondingly be prevented in the total population (the
attributable proportion in the total population, APt) are
33% and 10% respectively. They are achievable only
under the unrealistic assumption that no losses occur
along the trajectory from risk screening to intervention to
post-interventional maintenance. Based on consensus
strategies of categorizing as high-risk those with a greater
than 20% risk of CVD over the next 10 years [19], the
Framingham Risk Score (FRS) does not perform any better
than the MS. About two thirds of first incidents of heart
disease and stroke happen in individuals whose risk esti-
mation remains below that threshold [18].
A more promising approach may be a neural network
based prediction as developed from data of the prospec-
tive Cardiovascular Munster Study (PROCAM) [20]. With
sensitivity and specificity of 75% and 96% respectively
and a false positive rate of only 3% such a screening tool
could facilitate a reduction in disease prevalence of about
8%. That's under the assumption that a lifestyle interven-
tion would prevent 11% of cases in the screen-detected at-
risk individuals, which is the true prevention rate esti-
mated from prospective modeling of the DPS data [21].
The FRS and PROCAM risk engines are composites of
modifiable and un-modifiable parameters, the latter
being age, gender and, in the case of PROCAM, family his-
tory of CVD. As we cannot change un-modifiable param-
eters, the utility of these risk engines to gauge the potential
effect of risk reduction on incidence rates and prevalence
of CVD is limited.
The limited utility of screening has been acknowledged by
the U.S. Preventive Services Task Force (USPSTF). With
respect to diabetes, the USPSTF considers evidence to be
insufficient to recommend for or against routine screen-
ing of asymptomatic adults [22]. Screen-selecting high-
risk individuals for preventive intervention may, to some
degree, be a self-defeating exercise. For an individual the
stratification into the risk category that does not require
intervention may implicitly endorse a potentially harmful
lifestyle which has yet to manifest in clinically relevant
parameter aberrations. We thereby a) miss the window of
opportunity for marginalizing this potential health threat
and b) reinforce detrimental health habits. The latter com-
plicates the future process of lifestyle change once the
need for change has become evident from "red-shifted"
risk factors.
Thus a public health strategy that builds on risk stratifica-
tion and prognostication to institute healthy behaviors,
may ironically prevent the adoption of such behaviors in
the sub-population which currently contributes most of
the disease cases.
Inefficiencies of Intervention
If one defines 'success' as an intervention's ability to pro-
duce lasting improvements of dietary and physical activity
habits, available promotions and interventions have
shown less than encouraging performance.
In the UK the ACTIVE for LIFE campaign which aimed at
promoting an increase in physical activity, yielded no
measurable behavioral change at a cost of £ 3' Mio [23].
Typically 50% of the participants in physical activity pro-
grams will have dropped out by month 6 [24,25]. Among
the usually highly motivated participants in clinical trials
of popular diets, adherence rates hover around the 50%
mark for the initial 12 months [26].
Initial weight loss of 5–10% in obese persons have been
reported in weight reduction trials, however with almost
entire reversal of weight loss within 3–5 years [27]. In the
DPS, less than 40% of the lifestyle participants achieved
the weight loss goals, and the gradual regain of weight in
those randomized to the DPP lifestyle modification [8]
suggests a significant post-interventional decay of adher-
ence to lifestyle change. When defining long-term weight-
loss success of maintaining a 10% loss of bodyweight at
12 months, the most optimistic estimates of success rates
are 20% [28].
We see three reasons for this high degree of attrition:
1. inadequate consumerization
2. mismatch of chronic need vs. acute provision of inter-
vention
3. neglect of the phenotypeBMC Public Health 2009, 9:64 http://www.biomedcentral.com/1471-2458/9/64
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Inadequate Consumerization
To-date the curricula of lifestyle change interventions have
been based on clinical utility and health benefit. Whether
and how the interventions appeal to participants has
never been factored into their design. The result is a sub-
stantial disparity between what would attract at-risk indi-
viduals into preventive lifestyle change programs and
what these programs offer [29]. This situation frustrates
preventive public health efforts in two ways:
￿ Reducing at-risk individuals' willingness to participate
in lifestyle change interventions
￿ Loss of at-risk individuals to appealing but questionable
commercial programs
We posit that the success of a lifestyle change program
depends on its curriculum being matched to the targeted
individuals' preferences, abilities and environmental con-
straints.
Mismatch of chronic need vs. acute provision
Clinical interventions for the prevention of lifestyle dis-
ease are modeled around acute care, providing an inter-
vention for a limited period of time. The WHO considers
these systems as falling "remarkably short" when tasked
with preventing and managing chronic diseases [30].
Given the near constant exposure to the seductions of
injurious lifestyles, sustained vigilance is a necessity for
sustained success of lifestyle disease prevention.
Neglect of the phenotype
Treatment guidelines are typically developed from epide-
miological and clinical studies which have demonstrated
treatment effect by way of intention-to-treat analysis
(ITA). ITA evaluates control and intervention subjects as
part of the study groups to which they had originally been
randomized. As randomization provides for similar base-
line profiles across groups, outcome differences between
groups can be attributed to the study intervention.
ITA however does neither preclude inter-individual differ-
ences in treatment response nor does it make them show.
Aberrant response phenotypes may indeed cluster into
subgroups whose response to treatment varies due to dif-
ferences in genetic and epigenetic parameters. This effect
can be substantial as evidenced by the fact that only 25–
60% of patients benefit from most major drugs [31].
Lifestyle interventions are not different:
1. Physical fitness: Increasing maximal oxygen consump-
tion (VO2max) through aerobic activity is a key objective
of physical activity interventions aimed at improving car-
diovascular fitness. The yield ranges from dramatic
improvement to no improvement at all [32]. Moreover,
those individuals whose VO2max does not respond to aer-
obic training, may benefit from resistance training [33].
2. Blood pressure: One notable result of the Dietary
Approaches to Stop Hypertension (DASH) program were
the substantial inter-individually different blood pressure
responses to the depletion or repletion of sodium [34].
Correspondingly, while reductions in sodium intake have
yielded only marginal reductions in the general popula-
tion, some individuals show dramatic improvements
[35].
3. Body weight: In a 12-weeks volume-controlled physical
activity intervention aimed at reducing weight in 30 obese
subjects [36], the achieved mean weight loss masked sub-
stantial differences between individuals, ranging from 15
Kg weight reduction to slight weight gain. Variations in (a)
compensatory energy intake and (b) metabolic response
produced large differences in losses of fat and lean mass,
all of which remain hidden when data are reported as
group means only.
4. The fallacious "obese = risk" equation: Among the
(long-term) obese there exists a sub-group with normal
metabolic profiles, the metabolically healthy obese
(MHO). Correspondingly, the metabolically obese nor-
mal weight person (MONW) presents with the biochemi-
cal hallmarks of obesity but a normal body weight
[37,38]. The MHOs account for up-to one third of the
obese population and close to one in 4 normal-weight
persons presents with metabolic aberrations [38,39]. Dis-
regard of these phenotypical differences makes weight-
based selection strategies miss a substantial proportion of
at-risk individuals while wasting resources on those who
don't need them.
In the case of the individual patient with an "aberrant"
profile, medical/preventive intervention in accordance
with ITA informed guidelines will not only fail but also
potentially breed frustration and rejection of further pre-
ventive intervention.
In a nutshell
From screening to intervention to maintenance, the pro-
portion of at-risk individuals which remains or drops out
of our reach is simply too large to let us make any dent in
disease prevalence.
This begs the question
could simply treating everybody with lifestyle change
interventions be more beneficial than screening many,
treating some and thereby losing most? Disregarding the
cost factor the idea is not so far fetched. First, the aspects
of lifestyle interventions are consistent with current life-BMC Public Health 2009, 9:64 http://www.biomedcentral.com/1471-2458/9/64
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style recommendations to the general public. Second, the
diagnostics for monitoring the effects of lifestyle change
and optimizing the intervention are the same as the
screening diagnostics. The idea becomes appealing when
the costs for this alternative strategy are equal or less than
the costs of our current strategy. And it will spread across
populations once the return on investment (ROI) makes
population-wide intervention financially attractive to
those who pay for and benefit from the health of their
population – the health insurers and employers. Obvi-
ously cost effectiveness and economic returns are the
make-it-or-break-it for this idea.
Cost effectiveness
The saving grace for the limited reach of our current pre-
vention efforts would be their cost-effectiveness in treated
populations. Whether they are cost-effective, we can't say,
for two reasons:
￿ Methodical Inadequacy
￿ Modeling Uncertainty
Methodical Inadequacy
On a societal level the implementation of medical inter-
ventions generally follows favorable cost-utility analyses
(CUA). CUA compares the relative costs with the relative
health gains of different health interventions. The results
are typically expressed in dollars spent per quality
adjusted life year (QUALY) gained. Since CUA does not
attach a monetary value to its outcome measure, it avoids
ethical quagmires such as having to decide on the relative
values of health of a retired vs. a productively employed
person. But this reluctance to express a person's health in
dollar terms is a disincentive for developing preventive
interventions around favorable return on investment
(ROI). The latter would inevitably draw investments from
those for whom an individual's health yields a tangible
economic benefit – foremost his health insurance agency
and his employer. Their willingness to pay for its mainte-
nance is driven by the economic dictum of optimizing
profitability. In the German context where (a) health
insurance coverage is mandated for every resident and (b)
health insurance providers operate under competitive
market conditions, it is easy to see how a favorable rate of
return would drive the population-wide implementation
of preventive interventions. CUA however, not only fails
to provide such measure, it can't even give a reliable esti-
mate of what it is supposed to estimate: cost effectiveness.
The reason is modeling uncertainty.
Modeling Uncertainty
The per-capita cost of implementing the DPP has been
estimated at US$ 1,400.- and US$ 700.- (at year 2000 US$
values) for the first and each follow-up year respectively
[40]. That translates into cost-estimates ranging from US$
6,600.- [41] to US$ 62,600.- [21] per QUALY depending
on whether Markov or Archimedes modelling strategies
are being applied.
Whichever model we prefer, it's an exercise in crystal ball
gazing. Hence, little money is being spent for preventive
lifestyle change interventions. The OECD, acknowledging
that lifestyle has become a stronger determinant for health
than the provision of health care itself, allocates only
around 3% of its health budgets on preventive interven-
tions [42].
The beneficiaries of people's health need to know the
returns on their investments into preventing a deteriora-
tion of that health. However, while we don't have the
answer, it doesn't mean that we can't get it. What we need
to extract it is (a) a new way of post-hoc analysis of avail-
able study data (per-compliance analysis) and (b) a mod-
ified method of carrying out new studies (population-
wide intervention).
The Need for an Alternative Evaluation Method
Our body of knowledge enables us to formulate lifestyle
change interventions which could dramatically reduce
disease incidence in any given population [43-49]. Our
research objective could therefore broaden from testing
the associations between lifestyle change intervention and
cardiometabolic health to encompass testing the question
whether such interventions "buy" us a reduction in dis-
ease incidence at a favorable ROI. That would incorporate
an analytical focus on differential analyses of the compli-
ant vs the non-compliant sub-groups. ITA makes it impos-
sible to disentangle the effects of compliance on goal
achievement from the inter-group comparison. That is
because compliance and non-compliance "happens" in
both groups as the DPS trial has demonstrated, where
23% of those who complied with at least 4 of the 5 inter-
vention targets were controls [11]. Controls comply when
recruitment strategies attract subjects with a baseline
motivation that is high enough to pro-actively change
their health behaviors irrespective of their being rand-
omized into the control group.
At given per-capita costs the ROI depends (a) on the inter-
vention's effectiveness at reducing disease incidence in
compliant individuals and (b) on the degree of compli-
ance within the population. Obviously, the knowledge
about actual ROI lies still far in the future at the conclu-
sion of long-term longitudinal studies to ascertain inci-
dence rate reductions. That does not prevent us from
developing and testing interventions which maximize
compliance and effect at minimum cost. To compare
those new strategies with our current ones we need a
slightly different evaluation method. Its purpose will be toBMC Public Health 2009, 9:64 http://www.biomedcentral.com/1471-2458/9/64
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demonstrate (a) whether population-wide implementa-
tion produces interim surrogate outcome measures (e.g.
reduction in risk score or short-term incidence) compara-
ble to those tested in trials such as the DPP at equal or
lower costs, and (b) to make such studies of population-
wide interventions comparable across context popula-
tions.
Per-compliance evaluation
While outcome is generally a clearly defined event or an
objectively measurable parameter, compliance is a less
precise concept. In keeping with this definition and with
published elaborations on this subject we define compli-
ance as the degree to which a study subject conforms to a
prescribed intervention regimen [50]. To make compli-
ance truly measurable we therefore need to determine cut-
off values for the degree of compliance, which we consider
the threshold that separates the compliant from the non-
compliant subject. Doing so will enable us to apply the
evaluation method described in this section to post hoc
and comparative analyses of the cost-efficiency of studied
and published intervention strategies.
Here is how it works:
To estimate an intervention's effectiveness (E) at produc-
ing the target outcome we first need to estimate the out-
come that is attributable to the intervention. This is
obviously the number of outcome-positive subjects
among the compliant participants (O+|C+) minus the
number of outcome-positive subjects among the non-
compliant participants (O+|C-). The effect on the latter
cannot be attributed to the intervention. The result is then
to be multiplied with the proportion of compliant sub-
jects among the total study population C+/ΣS.
E = (O+|C+ - O+|C-) × C+/ΣS
E is a dimensionless parameter which facilitates the rela-
tive comparison of interventions' effectiveness at achiev-
ing similar outcomes. It is inversely proportional to the
cost of the intervention per outcome-positive subject
whose outcome is attributable to the intervention. Hence,
multiplying the inverse of E with the per-capita interven-
tion cost will yield the intervention's per-capita cost for
achieving the desired outcome. This facilitates a compari-
son in economic terms between intervention costs and
outcome values across different intervention strategies. It
also enables implementation agencies to translate the cost
effectiveness findings of any study into their specific con-
text. One has to keep in mind, however, that this value
informs about the cost of preventing disease only if dis-
ease incidents have been the outcome measure. If surro-
gate parameters have been used, such as risk factors, the
results solely facilitate the comparison of cost efficiencies
between interventions.
Tables 2 &3 illustrate the calculations based on a hypo-
thetical study population and on the DPS data [11]
respectively.
Consequences for Research
We began this discussion with the question whether our
enthusiasm for lifestyle change as a means to reduce the
cardiometabolic disease epidemic may be unjustified. We
have argued that it is not a lack of effectiveness of lifestyle
change per se, rather than an inefficient deployment of
screening and intervention strategies which keeps us from
winning the battle against this epidemic. As take-home
points we have highlighted the need for interventions to
be:
￿ consumerized to participants' expectations
￿ individualized to their phenotypes and
￿ perpetualized to counteract the modern environment's
constant temptations
However, it will be (a) our ability to create lifestyle change
interventions with favorable returns-on-investment and
(b) their population-wide application which will decide
the outcome of this battle. The former is not in conflict
with the tenets of ethics when there is no comparative
weighing of individuals' health, and the latter may even
be viewed as an ethical imperative. Since it is the consen-
sus view that our current body of knowledge justifies our
telling people that prudent lifestyle change will reduce
their cardiometabolic risk, the argument may be made
that we should discontinue randomizing people into con-
trol groups when we know from the outset that their peers
in the intervention group will enjoy significantly larger
health benefits.
Table 2: Calculation of efficiency
outcome + outcome - Total
compliant 56 14 70
non-compliant 62 4 30
Total 62 38 100
Tables values are based on the following assumptions:
• sample size n = 100 individuals
• compliance is 70%
• 80% of the compliant subjects have the desired outcome
• 20% of the non-compliant subjects have the desired outcome
E = ((56/70) - (6/30)) × (70/100) = 0.42
1/E = 2.38BMC Public Health 2009, 9:64 http://www.biomedcentral.com/1471-2458/9/64
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The impetus is on us researchers to develop and test such
interventions, and it is on the beneficiaries of individuals'
health to facilitate testing them.
The proposition of a population-wide intervention, spe-
cifically one that is individualized to each participant's
health/risk profile, is usually met with an off-the-cuff
objection of being too expensive and too labour intensive.
This is not necessarily so. As we have argued above, one
major reason for drop-out and post-interventional adher-
ence decay is a lack of concordance between the interven-
tions' curricula and a participant's idiosyncratic abilities,
preferences and environmental constraints. It is our expe-
rience (from ongoing and yet unpublished work) that tai-
loring a physical-activity intervention to an individual's
idiosyncratic profile is a one-time investment of effort and
time, which rewards both, the interventionist and the par-
ticipant, with substantially increased adherence and
effect. If this individualization of the intervention is com-
bined with telemetric adherence monitoring and interac-
tive behavior change technology (IBCT), the
interventionist can concentrate on those individuals who
require some extra effort, while not wasting it on those
who do not need it because they are "going it alone". We
currently test the deployment of telemetry and IBCT for
individualized preventive interventions on a population
level. One of our hypotheses being, that, across a subject
population, the inter-individually differing needs for
interventionist care will average to a sustainable and cost-
efficient level. If so, the results of our work may comple-
ment the current investigations into population strategies
for disease prevention.
Finland has taken that idea seriously and made it one of
three strategies to be tested within the framework of the
National Type 2 Diabetes Prevention Programme (FIN-
D2D) [51]. The other two being the high-risk strategy and
the strategy of early diagnosis and treatment. In the U.S.
the DEPLOY pilot study found the delivery of the DPP
intervention curriculum through YMCA community cent-
ers a promising and feasible alternative to clinical settings.
In Germany the National Action Forum Diabetes Mellitus
(NAFDM) has adopted the population strategy as part of
its national action plan [52]. The European DE-PLAN
("Diabetes in Europe – Prevention using Lifestyle, Physi-
cal Activity and Nutritional intervention") project cur-
rently tests the feasibility of translating research evidence
from prevention studies into efficient population strate-
gies [53].
All these efforts will advance our ability to design and
implement a population-wide intervention strategy which
effectively reduces disease incidence in a cost-efficient way
and without infringing on health care provider resources
needed for acute care. Within our German context, we feel
that the operationalization does not require expenditure
over and above those already being incurred for prevent-
ing cardiometabolic disease. Under current laws health
insurance agencies partially reimburse members' partici-
pation fees for self-selected primary prevention programs.
Program selection currently follows no discernible effi-
ciency criteria and is largely left to each individual mem-
ber's preferences. To substitute this practice for enrolling
all members of a regional population into a newly devel-
oped intervention for individualized and targeted preven-
tive lifestyle change is what a local health insurer currently
tests together in a pilot study with our group. We have
designed the intervention to maintain per-capita costs
below the annual ceiling of disbursements for preventive
efforts. We also deploy telemetric and interactive behavior
change technologies to allocate provider intervention
exactly as, when and at the intensity required to prevent
dropout and to optimize health benefits.
We encourage others to do likewise. The simple tools pre-
sented in this paper will facilitate a comparison of per-
formance across populations and designs. To paraphrase
the Olympic creed: the most important thing is not to win
but to take part.
Summary
Prudent health behaviors remain the first line of defence
against chronic lifestyle disease. But the current format of
reducing disease incidence through preventive lifestyle
change interventions is plagued by inefficiencies of
screening and intervention. We have argued that this inef-
ficiency is due to inadequacies of:
￿ screening: insufficient knowledge about the cause-effect
relationship between acknowledged parameters of disease
risk and disease outcome
Table 3: Calculation of efficiency based on the DPS data
outcome + outcome - Total
compliant 113 4 117
non-compliant 273 78 351
Total 386 82 468
the calculations are based on published data of the DPS [11]:
• sample size n = 468 individuals
• compliance (having achieved ≥ 3 goals) = 117 individuals
• 113 of the 117 compliant subjects had the desired outcome (no 
diabetes)
• 273 of the 351 non-compliant subjects had the desired outcome
• compliance in the intervention group: 87 of 235 subjects E = ((113/
117) - (273/351)) × (87/235) = 0.07
1/E = 14.3*
*At US$ 2,800 for a 3-year intervention, the prevention of one case 
of diabetes would cost 2,800 × 14.3 = US$ 40,040BMC Public Health 2009, 9:64 http://www.biomedcentral.com/1471-2458/9/64
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￿ intervention: lack of individualization and consumeri-
zation
We have consequently proposed
￿ To substitute a population strategy (i.e. individualized
interventions for all) for the high-risk strategy (i.e. stand-
ardized interventions to screen selected at-risk individu-
als).
￿ To apply a new method of appraising the cost efficiency
of preventive interventions for the purposes of making
such interventions comparable and to facilitate return-on-
investment estimates.
We have reasoned that the costs and efforts for individu-
alization will be more than offset by the resulting
increases in participants' adherence to lifestyle change
interventions and the long-term maintenance of acquired
prudent health behaviors. Additional economies of scale
may be realized through the deployment of telemetric and
interactive behavior change technology.
We have also argued that only when cardiometabolic
health can be expressed in economic terms of return-on-
investment will employers and health insurers be willing
and able to allocate more resources towards preventive
efforts for health maintenance. Once this state of affairs
has been reached, the population strategy will gain the
momentum of a positive feedback loop that has the
potential to finally put a dent into the epidemic of lifestyle
disease.
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